The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Ketamine—its pharmacology and therapeutic uses
white, P. F., Way, W. L., & Trevor, A. J. (1982) · Anesthesiology · doi:10.1097/00000542-198202000-00007 · Cited by 1,474
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
Jentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs
Olney, J. W., Labruyere, J., & Price, M. T. (1989) · Science · doi:10.1126/science.2660263 · Cited by 1,237
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · cited 1×
“Similar changes in the glutamatergic and dopaminergic systems were found in patients with schizophrenia (Kim et al., 1980; Tsai et al., 1995; Breier et al., 1997).”
ResultGABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Neuregulins: functions, forms, and signaling strategies
Falls, D. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00102-7 · Cited by 1,071
Hashimoto, T., Volk, D. W., Eggan, S. M., Mirnics, K., Pierri, J. N., Sun, Z., Sampson, A. R., & Lewis, D. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06315.2003 · Cited by 938
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
Lahti, A. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 921
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor ε1 subunit
Sakimura, K., Kutsuwada, T., Ito, I., Manabe, T., Takayama, C., Kushiya, E., Yagi, T., Aizawa, S., Inoue, Y., Sugiyama, H., et al. (1995) · Nature · doi:10.1038/373151a0 · Cited by 859
NMDA Antagonist Neurotoxicity: Mechanism and Prevention
Olney, J. W., Labruyere, J., Wang, G., Wozniak, D. F., Price, M. T., & Sesma, M. A. (1991) · Science · doi:10.1126/science.1835799 · Cited by 841
Cognitive Impairment in Schizophrenia Is the Core of the Disorder
Elvevag, B., & Goldberg, T. E. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i1.10 · Cited by 835 · cited 2×
“to be the primary and persistent manifestation in patients with schizophrenia (Elvevag and Goldberg, 2000; Keefe et al., 2006; Andreasen, 1999).”
BackgroundLow cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., & Holzmüller, B. (1980) · Neuroscience Letters · doi:10.1016/0304-3940(80)90178-0 · Cited by 694
Interactions Between Monoamines, Glutamate, and GABA in Schizophrenia: New Evidence
Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M., & Carlsson, M. L. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.237 · Cited by 688
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers
Malhotra, A. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680
To Model a Psychiatric Disorder in Animals Schizophrenia As a Reality Test
Lipska, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00137-8 · Cited by 650
A Unitary Model of Schizophrenia: Bleuler's "Fragmented Phrene" as Schizencephaly
Andreasen, N. C. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.9.781 · Cited by 610
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585
Provocative tests with psychostimulant drugs in schizophrenia
Lieberman, J. A., Kane, J. M., & Alvir, J. (1987) · Psychopharmacology · doi:10.1007/bf00216006 · Cited by 532
Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death
Forrest, D., Yuzaki, M., Soares, H. D., Ng, L., Luk, D. C., Sheng, M., Stewart, C. L., Morgan, J. I., Connor, J. A., & Curran, T. (1994) · Neuron · doi:10.1016/0896-6273(94)90350-6 · Cited by 491 · cited 1×
“Mice with full deletion of the gene for the NR1 subunit die immediately after birth (Forrest et al., 1994).”
BackgroundThe phenomenology of experimentally induced amphetamine psychosis--preliminary observations.
ANGRIST, B. M., & Gershon, S. (1970) · PubMed · Cited by 477
Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455
Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia
Mirnics, K., Middleton, F. A., Stanwood, G. D., Lewis, D. A., & Levitt, P. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000866 · Cited by 446
Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia
COYLE, J. T., TSAI, G., & GOFF, D. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.020 · Cited by 442
Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors.
Oye, I., Paulsen, O., & Maurset, A. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11430-4 · Cited by 429
Bringing Order to the Glutamate Chaos in Schizophrenia
Moghaddam, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00757-8 · Cited by 403
Jentsch, J. D., Redmond, D. E., Elsworth, J. D., Taylor, J. R., Youngren, K. D., & Roth, R. H. (1997) · Science · doi:10.1126/science.277.5328.953 · Cited by 398
Théberge, J., Bartha, R., Drost, D. J., Menon, R. S., Malla, A., Takhar, J., Neufeld, R. W., Rogers, J., Pavlosky, W., Schaefer, B., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1944 · Cited by 398
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Lipska, B. K., Weinberger, D. R., Swerdlow, N. R., Geyer, M. A., Braff, D. L., & Jaskiw, G. E. (1995) · Psychopharmacology · doi:10.1007/bf02246439 · Cited by 357
Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Antonini, A., Maguire, P., Missimer, J., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00039-9 · Cited by 353
Sanders, A. R., Duan, J., Levinson, D. F., Shi, J., He, D., Hou, C., Burrell, G. J., Rice, J. P., Nertney, D. A., Olincy, A., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07101573 · Cited by 349
Ligand-Gated Ion Channel Interactions with Cytoskeletal and Signaling Proteins
Sheng, M., & Pak, D. T. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.755 · Cited by 349
Angrist, B., Rotrosen, J., & Gershon, S. (1980) · Psychopharmacology · doi:10.1007/bf00433802 · Cited by 344
Adler, C. M., Malhotra, A. K., Elman, I., Goldberg, T., Egan, M., Pickar, D., & Breier, A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.10.1646 · Cited by 337
Jentsch, J. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00034-1 · Cited by 320
Benson, M. A., Newey, S. E., Martin-Rendon, E., Hawkes, R., & Blake, D. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010418200 · Cited by 304
First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients
Pilowsky, L. S., Bressan, R. A., Stone, J. M., Erlandsson, K., Mulligan, R. S., Krystal, J. H., & Ell, P. J. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001751 · Cited by 278
Memantine: A Review of Its Use in Alzheimer’s Disease
Robinson, D. M., & Keating, G. M. (2006) · Drugs · doi:10.2165/00003495-200666110-00015 · Cited by 277
A longitudinal study of neurocognitive function in individuals at-risk for psychosis
Keefe, R. S. E., Perkins, D. O., Gu, H., Zipursky, R. B., Christensen, B. K., & Lieberman, J. A. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.041 · Cited by 263
NMDA receptors and schizophrenia
KRISTIANSEN, L., HUERTA, I., BENEYTO, M., & MEADORWOODRUFF, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.013 · Cited by 246
On the Plausibility of “The Neurodevelopmental Hypothesis” of Schizophrenia
Weinberger, D. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00199-n · Cited by 245
Interactive effects of subanesthetic ketamine and haloperidol in healthy humans
Krystal, J. H., D'Souza, D. C., Karper, L. P., Bennett, A., Abi-Dargham, A., Abi-Saab, D., Cassello, K., Bowers Jr., M. B., Vegso, S., Heninger, G. R., et al. (1999) · Psychopharmacology · doi:10.1007/s002130051049 · Cited by 243
Neurofunctional deficits and potentiated apoptosis by neonatal NMDA antagonist administration
Fredriksson, A., Archer, T., Alm, H., Gordh, T., & Eriksson, P. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.12.026 · Cited by 241
Rujescu, D., Bender, A., Keck, M., Hartmann, A. M., Ohl, F., Raeder, H., Giegling, I., Genius, J., McCarley, R. W., Möller, H.-J., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.029 · Cited by 239
Långsjö, J. W., Kaisti, K. K., Aalto, S., Hinkka, S., Aantaa, R., Oikonen, V., Sipilä, H., Kurki, T., Silvanto, M., & Scheinin, H. (2003) · Anesthesiology · doi:10.1097/00000542-200309000-00016 · Cited by 239
Cochran, S. M., Kennedy, M., McKerchar, C. E., Steward, L. J., Pratt, J. A., & Morris, B. J. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300031 · Cited by 236
Sharp, F. R., Jasper, P., Hall, J., Noble, L., & Sagar, S. M. (1991) · Annals of Neurology · doi:10.1002/ana.410300609 · Cited by 235
Wang, C., McInnis, J., Ross-Sanchez, M., Shinnick-Gallagher, P., Wiley, J. L., & Johnson, K. M. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00384-0 · Cited by 234
Krystal, J. (1999) · Harvard Review of Psychiatry · doi:10.1093/hrp/7.3.125 · Cited by 232
Bartha, R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830220085012 · Cited by 231
Vollenweider, F. X., Vontobel, P., Øye, I., Hell, D., & Leenders, K. L. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00031-x · Cited by 223
Breier, A., Adler, C. M., Weisenfeld, N., Su, T.-P., Elman, I., Picken, L., Malhotra, A. K., & Pickar, D. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199806)29:2<142::aid-syn5>3.0.co;2-7 · Cited by 201
Smith, P. D. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00092-4 · Cited by 201
Keilhoff, G., Becker, A., Grecksch, G., Wolf, G., & Bernstein, H.-G. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.03.039 · Cited by 199
Ghoneim (1985) · doi:10.1097/00004714-198504000-00003 · Cited by 196
Duncan, G. E., Moy, S. S., Perez, A., Eddy, D. M., Zinzow, W. M., Lieberman, J. A., Snouwaert, J. N., & Koller, B. H. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.01.008 · Cited by 194
Herdegen, T., Kovary, K., Buhl, A., Bravo, R., Zimmermann, M., & Gass, P. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903540105 · Cited by 190
Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
Krystal, J. H., Karper, L. P., Bennett, A., D'Souza, D. C., Abi-Dargham, A., Morrissey, K., Abi-Saab, D., Bremner, J. D., Bowers Jr., M. B., Suckow, R. F., et al. (1998) · Psychopharmacology · doi:10.1007/s002130050503 · Cited by 184
López-Gil, X., Babot, Z., Amargós-Bosch, M., Suñol, C., Artigas, F., & Adell, A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301356 · Cited by 183 · cited 1×
“MK-801 into rat prefrontal cortex lacked any effect on serotonin and glutamate levels (López-Gil et al., 2007).”
Background"Psychedelic" Experiences in Acute Psychoses
BOWERS, M. B. (1966) · Archives of General Psychiatry · doi:10.1001/archpsyc.1966.01730150016003 · Cited by 182
O’Tuathaigh, C. M. P., Babovic, D., O’Meara, G. F., Clifford, J. J., Croke, D. T., & Waddington, J. L. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.04.002 · Cited by 166
A Revised Excitotoxic Hypothesis of Schizophrenia: Therapeutic Implications
Deutsch, S. I., Rosse, R. B., Schwartz, B. L., & Mastropaolo, J. (2001) · Clinical Neuropharmacology · doi:10.1097/00002826-200101000-00008 · Cited by 166
Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats
Sams‐Dodd, F. (1995) · Behavioural Pharmacology · doi:10.1097/00008877-199501000-00009 · Cited by 164
Long‐term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism
Wiseman Harris, L., Sharp, T., Gartlon, J., Jones, D. N. C., & Harrison, P. J. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02902.x · Cited by 162
Clinical and Sensorimotor Gating Effects of Ketamine in Normals
Duncan, E., Madonick, S. H., Parwani, A., Angrist, B., Rajan, R., Chakravorty, S., Efferen, T. R., Szilagyi, S., Stephanides, M., Chappell, P. B., et al. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00240-2 · Cited by 162
Stefani, M. R., & Moghaddam, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.031 · Cited by 157 · cited 5×
“Following early NMDA receptor inhibition, both working and reference memory in the Morris water maze are impaired in adult rats (Gorter and de Bruin, 1992; Sircar and Rudy, 1998; Wang et al., 2001; Sircar, 2003; Stefani and Moghaddam, 2005; Pehrson et al., 2007).”
BackgroundMethodResultInfluentialSams‐Dodd, F. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00200-5 · Cited by 154
van Berckel, B. N. M., Oranje, B., van Ree, J. M., Verbaten, M. N., & Kahn, R. S. (1998) · Psychopharmacology · doi:10.1007/s002130050620 · Cited by 148
Freedman, D. X. (1968) · Archives of General Psychiatry · doi:10.1001/archpsyc.1968.01740030074008 · Cited by 145
Ballard, T. M., Pauly-Evers, M., Higgins, G. A., Ouagazzal, A., Mutel, V., Borroni, E., Kemp, J. A., Bluethmann, H., & Kew, J. N. C. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06713.2002 · Cited by 141
Yonezawa, Y., Kuroki, T., Kawahara, T., Tashiro, N., & Uchimura, H. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01435-0 · Cited by 141
Amphetamine psychosis and psychotic symptoms
Janowsky, D. S., & Risch, C. (1979) · Psychopharmacology · doi:10.1007/bf00491982 · Cited by 140
Imre, G., Fokkema, D. S., den Boer, J. A., & Horst, G. J. T. (2006) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2006.01.010 · Cited by 134
Duncan, G. E., Moy, S. S., Knapp, D. J., Mueller, R. A., & Breese, G. R. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01390-5 · Cited by 129
The psychedelic model of schizophrenia: the case of N,N- dimethyltryptamine
Gillin, J. C., Kaplan, J., Stillman, R. C., & Wyatt, R. J. (1976) · American Journal of Psychiatry · doi:10.1176/ajp.133.2.203 · Cited by 127
Early brain development disruption from NMDA receptor hypofunction: Relevance to schizophrenia
du Bois, T. M., & Huang, X. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.09.001 · Cited by 123
Benes, F. M. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033322 · Cited by 120
Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats
Martin, P., Carlsson, M. L., & Hjorth, S. (1998) · Neuroreport · doi:10.1097/00001756-199809140-00012 · Cited by 119
Abekawa, T., Ito, K., Nakagawa, S., & Koyama, T. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0729-8 · Cited by 118
Duncan, G. E., Miyamoto, S., Leipzig, J. N., & Lieberman, J. A. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01776-x · Cited by 117
Muscimol: GABA agonist therapy in schizophrenia
Tamminga, C. A., Crayton, J. W., & Chase, T. N. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.6.746 · Cited by 117
Low dose ketamine increases prepulse inhibition in healthy men
Abel, K. M., Allin, M. P. G., Hemsley, D. R., & Geyer, M. A. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00073-x · Cited by 114
Possible Mechanisms of Neurodegeneration in Schizophrenia
Pérez‐Neri, I., Ramírez‐Bermúdez, J., Montes, S., & Ríos, C. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9162-3 · Cited by 111
Wang, C., McInnis, J., West, J. B., Bao, J., Anastasio, N. C., Guidry, J. A., Ye, Y., Salvemini, D., & Johnson, K. M. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041798 · Cited by 107
Chronic neonatal MK-801 treatment results in an impairment of spatial learning in the adult rat
Gorter, J. A., & de Bruin, J. P. C. (1992) · Brain Research · doi:10.1016/0006-8993(92)90921-u · Cited by 103
Modulating sensory gating in healthy volunteers
Oranje, B., Gispen-de Wied, C. C., Verbaten, M. N., & Kahn, R. S. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01377-x · Cited by 98
Large, C. H. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077712 · Cited by 98
Mouri, A., Noda, Y., Noda, A., Nakamura, T., Tokura, T., Yura, Y., Nitta, A., Furukawa, H., & Nabeshima, T. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.032961 · Cited by 98
Mandillo, S., Rinaldi, A., Oliverio, A., & Mele, A. (2003) · Behavioural Pharmacology · doi:10.1097/00008877-200311000-00006 · Cited by 97
Jentsch, J. D., Tran, A., Taylor, J. R., & Roth, R. H. (1998) · Psychopharmacology · doi:10.1007/s002130050649 · Cited by 97
Radant, A. D., Bowdle, T. A., Cowley, D. S., Kharasch, E. D., & Roy-Byrne, P. P. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00030-x · Cited by 97
Bubeníková, V., Votava, M., Horáček, J., Páleníček, T., & Dockery, C. A. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.012 · Cited by 91
Self-citationCanguilhem, G. (1978) · Springer eBooks · doi:10.1007/978-94-009-9853-7_12 · Cited by 87
Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations
Jarskog, L. F. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000218603.25346.8f · Cited by 86
McCullough, L. D., & Salamone, J. D. (1992) · Brain Research · doi:10.1016/0006-8993(92)90530-m · Cited by 85
Clozapine Prevents a Decrease in Neurogenesis in Mice Repeatedly Treated With Phencyclidine
Maeda, K., Sugino, H., Hirose, T., Kitagawa, H., Nagai, T., Mizoguchi, H., Takuma, K., & Yamada, K. (2007) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0061424 · Cited by 84
Glial–Neuronal Interactions are Impaired in the Schizophrenia Model of Repeated MK801 Exposure
Kondziella, D., Brenner, E., Eyjolfsson, E. M., Markinhuhta, K. R., Carlsson, M. L., & Sonnewald, U. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300993 · Cited by 82
DUNCAN, G., MOY, S., LIEBERMAN, J., & KOLLER, B. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.09.017 · Cited by 82
Sircar, R. (2003) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(03)00026-1 · Cited by 81
Ketamine Effects on Eye Movements
Weiler, M. A., Thaker, G. K., Lahti, A. C., & Tamminga, C. A. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00156-1 · Cited by 80
Emamian, E. S., Karayiorgou, M., & Gogos, J. A. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4650-03.2004 · Cited by 80
Postnatal Development of Glutamate Receptor-Mediated Responses in the Neostriatum
Colwell, C. S., Cepeda, C., Crawford, C. A., & Levine, M. S. (1998) · Developmental Neuroscience · doi:10.1159/000017310 · Cited by 78
Gu, Z., Jiang, Q., & Yan, Z. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.032490 · Cited by 75
The schizophrenia ketamine challenge study debate
Carpenter, W. T. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00194-8 · Cited by 73
NMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys
Adams, B. W., Bradberry, C. W., & Moghaddam, B. (2001) · Synapse · doi:10.1002/syn.1114 · Cited by 70
Morrow, B. A., Elsworth, J. D., & Roth, R. H. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0708-0 · Cited by 70
Soyka, M., Koch, W., Möller, H. ‐., Rüther, T., & Tatsch, K. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0563-0 · Cited by 68
Association of symptoms and executive function in schizophrenia and bipolar disorder
Kravariti, E., Dixon, T., Frith, C., Murray, R. M., & McGuire, P. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.06.008 · Cited by 67
Enomoto, T., Noda, Y., & NABESHIMA, T. (2007) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2007.29.4.1075358 · Cited by 66
Bressan, R. A., Erlandsson, K., Stone, J. M., Mulligan, R. S., Krystal, J. H., Ell, P. J., & Pilowsky, L. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.016 · Cited by 65
Zuo, D., Zhang, Y., Cao, Y., Wu, C., Tanaka, M., & Wu, Y. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.022 · Cited by 65
Baldridge, E. B., & Bessen, H. A. (1990) · Emergency Medicine Clinics of North America · doi:10.1016/s0733-8627(20)30258-3 · Cited by 64
Thalamic and Prefrontal FDG Uptake in Never Medicated Patients With Schizophrenia
Lehrer, D. S., Christian, B. T., Mantil, J., Murray, A. C., Buchsbaum, B. R., Oakes, T. R., Byne, W. M., Kemether, E. M., & Buchsbaum, M. S. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.931 · Cited by 63
Duncan, G. E., Miyamoto, S., Gu, H., Lieberman, J. A., Koller, B. H., & Snouwaert, J. N. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03156-6 · Cited by 61
Stoet, G., & Snyder, L. H. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300930 · Cited by 61
Qin, Z., Zhang, S., & Weiss, B. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90260-7 · Cited by 60
Dysbindin-1 and schizophrenia: from genetics to neuropathology
Owen, M. J., Williams, N. M., & O’Donovan, M. C. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421470 · Cited by 59
Takeuchi, T., Kiyama, Y., Nakamura, K., Tsujita, M., Matsuda, I., Mori, H., Munemoto, Y., Kuriyama, H., Natsume, R., Sakimura, K., et al. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01620.x · Cited by 58
Abekawa, T., Ito, K., Nakagawa, S., Nakato, Y., & Koyama, T. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.488 · Cited by 58
Takahashi, M., Kakita, A., Futamura, T., Watanabe, Y., Mizuno, M., Sakimura, K., Ċastrén, E., Nabeshima, T., Someya, T., & Nawa, H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04106.x · Cited by 54
Lee, H., & Choi, B. H. (1992) · Experimental Neurology · doi:10.1016/0014-4886(92)90185-s · Cited by 53
Avila, M. T., Weiler, M. A., Lahti, A. C., Tamminga, C. A., & Thaker, G. K. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1490 · Cited by 53
Valeš, K., Bubeníková‐Valešová, V., Klement, D., & Stuchlı́k, A. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.007 · Cited by 52
Self-citationCheli, V. T., Adrover, M. F., Blanco, C., Ferrari, C. C., Cornea, A. M., Pitossi, F. J., Epstein, A. L., & Jerusalinsky, D. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03592.x · Cited by 52
Wang, C., Anastasio, N. C., Popov, V., LeDay, A. M., & Johnson, K. M. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.02.003 · Cited by 51
Long-term outcome of patients who receive ketamine during research
Lahti, A. C., Warfel, D. T., Michaelidis, T., Weiler, M. A., Frey, K., & Tamminga, C. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01037-4 · Cited by 51
Yu, B., Wang, C., Liu, J., Johnson, K. M., & Gallagher, J. P. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00163-x · Cited by 44
Long-term effects of developmental PCP administration on sensorimotor gating in male and female rats
Rasmussen, B. A., O’Neil, J. N., Manaye, K. F., Perry, D. C., & Tizabi, Y. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0584-z · Cited by 41
Kajimoto, Y., Shirakawa, O., Lin, X., Hashimoto, T., Kitamura, N., Murakami, N., Takumi, T., & Maeda, K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300212 · Cited by 41
Iasevoli, F., Polese, D., Ambesi-Impiombato, A., Muscettola, G., & de Bartolomeis, A. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.01.041 · Cited by 40
Sircar, R., Follesa, P., & Ticku, M. K. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(96)00051-4 · Cited by 40
Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates
Shiigi, Y., & Casey, D. E. (1999) · Psychopharmacology · doi:10.1007/s002130051089 · Cited by 38
Zhuravliova, E., Barbakadze, T., Natsvlishvili, N., & Mikeladze, D. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.09.015 · Cited by 37
Sensitization of prepulse inhibition deficits by repeated administration of dizocilpine
Schulz, B., Fendt, M., Pedersen, V., et al. (2001) · Psychopharmacology · doi:10.1007/s002130100776 · Cited by 33
Physiology and pathology of NMDA receptors.
Petrović, M., Hořák, M., Sedlacek, M., & Vyklický, L. (2005) · PubMed · Cited by 33
Hollmann, M., Boulter, J., Maron, C., et al. (1994) · PubMed · Cited by 32
Pharmacologic Studies of the Neuroprotective Actions of a Glutamate Antagonist in Ischemia
Kochhar, A., Zivin, J. A., & Mazzarella, V. (1991) · Journal of Neurotrauma · doi:10.1089/neu.1991.8.175 · Cited by 29
Miyamoto, S., Snouwaert, J. N., Koller, B. H., Moy, S. S., Lieberman, J. A., & Duncan, G. E. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300548 · Cited by 29
Linn, G. S., O’Keeffe, R. T., Lifshitz, K., Schroeder, C. E., & Javitt, D. C. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0771-6 · Cited by 28
Hatip‐Al‐Khatib, I., 三島, 健., Iwasaki, K., & Fujiwara, M. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02382-4 · Cited by 23
Bubeníková‐Valešová, V., Balcar, V. J., Tejkalová, H., Langmeier, M., & Šťastný, F. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.01.019 · Cited by 22
Self-citationRepeated Neonatal Phencyclidine Treatment Impairs Performance of a Spatial Task in Juvenile Ratsa
Sircar, R., & Rudy, J. W. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb08244.x · Cited by 21
Inada, K., Ishigooka, J., Anzai, T., Suzuki, E., Miyaoka, H., & Saji, M. (2003) · Neuroscience Research · doi:10.1016/s0168-0102(03)00012-9 · Cited by 20
Howland, J. G., Hannesson, D. K., & Phillips, A. G. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03731.x · Cited by 20
Wędzony, K., Fijał, K., & Chocyk, A. (2005) · PubMed · Cited by 19
Zajaczkowski, W., Czyrak, A., & Wedzony, K. (2003) · PubMed · Cited by 14
Cited by
Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes
Belforte, J. E., Zsiros, V., Sklar, E. R., Jiang, Z., Yu, G., Li, Y., Quinlan, E. M., & Nakazawa, K. (2010) · Nature Neuroscience · doi:10.1038/nn.2447 · Cited by 752
GABAergic interneuron origin of schizophrenia pathophysiology
Nakazawa, K., Zsiros, V., Jiang, Z., Nakao, K., Kolata, S., Zhang, S., & Belforte, J. E. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.022 · Cited by 498
“This heightened sensitivity of PV-containing neurons to NMDAR antagonists compared to the non-PV interneurons has been consistently reported across animals and the timing and dose of administration (Bubeníková-Valesová et al., 2008) and in cell cultures of interneurons (Kinney et al., 2006).”
BackgroundMicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction
Kocerha, J., Faghihi, M. A., Lopez-Toledano, M. A., Huang, J., Ramsey, A. J., Caron, M. G., Sales, N., Willoughby, D., Elmen, J., Hansen, H. F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805854106 · Cited by 295
Ayhan, Y., Abazyan, B., Nomura, J., Kim, R., Ladenheim, B., Krasnova, I. N., Sawa, A., Margolis, R. L., Cadet, J. L., Mori, S., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2009.144 · Cited by 148
Ketamine Disrupts Theta Modulation of Gamma in a Computer Model of Hippocampus
Neymotin, S. A., Lazarewicz, M. T., Sherif, M., Contreras, D., Finkel, L. H., & Lytton, W. W. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0501-11.2011 · Cited by 139
Metadata
- Authors
- Bubeníková-Valešová, V., Horáček, J., Vrajová, M., & Höschl, C.
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2008-07
- Volume
- 32
- Issue
- 5
- Pages
- 1014-1023
- ISSN
- 0149-7634 (ISSN-L)
- OpenAlex
- W2099989397
- Cited by
- 336
- References
- 160
- FWCI
- 14.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.